CAR-T and CAR-NK Cell

Tristem Medika Indonesia will also develop Chimeric antigen receptor (CAR) T cell therapy and Chimeric antigen receptor (CAR) NK cell therapy.

CAR T cell therapy is an approach that uses its own immune cells to attack cancer cells and has shown promising results in treating some types of blood cancers. CAR T cell therapy involves isolating T cells from the blood and inserting a new gene into those cells that enable them to recognize and attack cancer. After the gene is inserted, the T cells are infused back into the bloodstream, where they multiply and initiate a variety of immune responses aimed at attacking the cancer cells. CAR-T use to treat cancer, primarily for blood cancers like leukemia and lymphoma.

Similar to CAR-T, CAR-NK cell therapy involves isolation and alteration of immune cells; however, this therapy uses NK cells instead of T cells. Unlike CAR-T cells, CAR-NK cells are able to penetrate solid tumors, making them able to fight various types of cancer.